ERBB2 and breast carcinoma: Some nanobody-based antibody drugs have been used in preclinical and clinical applications, such as the 68Ga-HER2-nanobody used in Phase 1 of HER2-positive breast carcinoma, which demonstrated obvious efficacy after PET/CT assessment [102].